Phase II trial begins for integrase-based, single-tablet, once-daily regimen.
D002985:Clinical Protocols; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019429:Integrase Inhibitors / Q000008:administration & dosage*; D013607:Tablets
D019429:Integrase Inhibitors; D013607:Tablets